Allarity Therapeutics, Inc. — fact timeline

Allarity Therapeutics, Inc. shareholders approved To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal at the 2023-06-23 meeting.

“Proposal 2 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (“Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 27,928,931 4,899,237 103,974 -”

Allarity Therapeutics, Inc. shareholders approved To approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-50 at the 2023-06-23 meeting.

“Proposal 1 : To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-15 and 1-for-50 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board, subject to the consent of the holder of Series A Preferred Stock (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 24,984,901 7,906,612 40,629 -”

Allarity Therapeutics, Inc.: Amendment to Certificate of Designations to modify voting rights of Series A Preferred Stock (effective 2023-05-30).

“On May 30, 2023, the Company filed a First Certificate of Amendment to Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock (the “Amended COD”) to amend and restate the voting provisions of the Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock, which was originally filed with the Secretary of State of the State of Delaware on April 21, 2023.”

Allarity Therapeutics, Inc. amended Amendment to Modification and Exchange Agreement with 3i, LP valued at Correction of share count from 4,027 to 5,577 shares of Series A Preferred Stock (effective 2023-04-20).

“On May 26, 2023, the Company and 3i entered into an Amendment to Modification and Exchange Agreement (the “Amendment”), effective as of April 20, 2023, to correct an error relating to the Original Shares in the Original Agreement. Due to an error in not taking into account the proposed redemption of 1,550 share of Series A Preferred Stock, the Original Agreement incorrectly referenced “4,027” shares of Series A Preferred Stock instead of “ 5,577.” Accordingly, the Amendment corrects such error and memorializes that the parties originally agreed to exchange the Series C Shares for 5,577 shares of Series A Preferred Stock.”

Allarity Therapeutics, Inc. amended Fourth Amendment to the Exclusive License Agreement with Eisai, Inc. valued at Periodic payments: $100,000 paid; $50,000 within 10 days; $100,000 upon capital raise; $850,000 by M (effective 2023-05-16).

“On May 26, 2023, the Company and Eisai entered into a Fourth Amendment to the Exclusive License Agreement with an effective date of May 16, 2023 (the “Eisai Amendment”), to postpone the extension payment, restructure the payment schedule and extend the deadline to complete enrollment in a further Phase 1b or Phase 2 Clinical Trial for the Stenoparib (the “Product”). Under the Eisai Amendment, the Company agreed to pay Eisai in periodic payments as follows: (i) one hundred thousand dollars ($100,000) which has been paid; (ii) fifty thousand dollars ($50,000) within ten (10) days of execution of the fourth amendment; (iii) one hundred thousand dollars ($100,000) upon completion of a capital raise; and (iv) eight hundred and fifty thousand dollars ($850,000) on or before March 1, 2024. The Company will have until April 1, 2024, to complete enrollment in a further Phase 1b or Phase 2 Clinical Trial of the Product. If the Company has not achieved successful completion of a further Phase 1b”

Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“May 23, 2023, the Company received a letter from the Nasdaq Regulation staff (“Letter”) stating that the Company did not regain compliance under the Rule by May 22, 2023, and such non-compliance will serve as an additional basis for delisting of the Company’s common stock from The Nasdaq Stock Market. Further, the Nasdaq Hearings Panel, which on May 18, 2023, heard the Company’s appeal for non-compliance with the stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5450(b)(1)(A), will consider the Letter in their decision regarding the Company’s continued listing on The Nasdaq”

Allarity Therapeutics, Inc.: Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock to eliminate redemption right and dividend and adjust conversion price (effective 2023-04-21).

“On April 21, 2023, in connection with the transactions contemplated under the Exchange Agreement, the Company filed an Amended and Restated Certificate of Designations of Series A Convertible Preferred Stock of the Company (the “Amended and Restated Series A COD”) with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”).”

Allarity Therapeutics, Inc. entered into Modification and Exchange Agreement with 3i, LP (effective 2023-04-20).

“On April 20, 2023, the Company entered into a certain Modification and Exchange Agreement (the “Exchange Agreement”) with 3i”

Allarity Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at a cash fee equal to 7.0% of the aggregate gross proceeds of the Offering and up to $150,000 in aggre (effective 2023-04-19).

“Concurrently with the Purchase Agreement, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“AGP”).”

Allarity Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers valued at aggregate gross proceeds of approximately $7.5 million (effective 2023-04-19).

“The Securities were sold pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with each purchaser identified on the signature pages thereto”

Allarity Therapeutics, Inc. incurred convertible notes of $350,000 with 3i, LP at 5% per annum maturing January 1, 2024.

“On April 11, 2023, 3i purchased an additional note for an aggregate amount of $350,000, which purchase price was paid for in cash. Each note issued under the Purchase Agreement matures on January 1, 2024, carries an interest rate of at 5% per annum, and is secured by all of the Company’s assets pursuant to a security agreement”

Allarity Therapeutics, Inc. amended First Amendment to the Secured Note Purchase Agreement with 3i, LP valued at aggregate principal amount of $2,666,640 (effective 2023-04-10).

“Allarity Therapeutics, Inc. (“we,” “our,” or the “Company”) entered into a First Amendment to the Secured Note Purchase Agreement dated April 10, 2023 (the “First Amendment”) with 3i, LP (“3i”), the sole holder of our Series A Convertible Preferred Stock”

Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“April 11, 2023, we received notification from the Nasdaq Listing Qualifications staff that it has determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Form 8-K by the April 10, 2023 deadline, evidencing compliance with the Rule. As a result, the Company’s securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of such determination, trading of the Company’s Common Stock will be suspended at the opening of business on April 20, 20”

Allarity Therapeutics, Inc.: Effected a 1-for-35 reverse stock split of common stock via amendment to Certificate of Incorporation (effective 2023-03-24).

“On March 23, 2023, the Company filed a Third Certificate of Amendment of Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-35 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 4:05 p.m. (New York time) on March 24, 2023 (the “Reverse Stock Split”).”

Allarity Therapeutics, Inc.: Increased authorized shares from 30,500,000 to 750,500,000 and common stock from 30,000,000 to 750,000,000 (effective 2023-03-20).

“an amendment to Allarity Therapeutics, Inc.’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of shares of common stock (the “Common Stock”) from 30,000,000 to 750,000,000 (the “Share Increase”) was approved”

Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-20 and 1-for-35, at the discretion of the Board at the 2023-03-20 meeting.

“Proposal 2: To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-20 and 1-for-35 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 34,308,947 361,101 18,333 -”

Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to increase authorized shares from 30,500,000 to 750,500,000 and Common Stock from 30,000,000 to 750,000,000 at the 2023-03-20 meeting.

“Proposal 1: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of our Common Stock from 30,000,000 to 750,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 34,265,983 410,898 11,500 -”

Allarity Therapeutics, Inc.: Filed certificate of amendment to Series C COD to clarify conversion price and floor price (effective 2023-02-28).

“On February 28, 2023, the Company filed a certificate of amendment to the Series C COD (the “COD Amendment”) to clarify the terms of conversion price and floor price based on definitions provided in the Series C COD”

Allarity Therapeutics, Inc.: Filed Certificate of Designation of Series C Preferred Stock (effective 2023-02-24).

“Pursuant to the terms of the SPA, on February 24, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (the “Series C COD”) with the Delaware Secretary of State designating 50,000 shares of its authorized and unissued preferred stock as Series C Preferred Stock with a stated value of $27.00 per share (the “Stated Value”).”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(b)(1)(A), 5605(c)(4)).

“February 8, 2023, Allarity Therapeutics, Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the resignation of Soren G. Jensen from the Company’s board and audit committee, effective on February 4, 2023, the Company no longer complies with Nasdaq’s independent director and audit committee requirements as set forth in Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4) which requires a majority of the board of directors to be comprised of independent directors and an audit committee of at least three independent dire”

Allarity Therapeutics, Inc. shareholders approved To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Share Increase Proposal or the Reverse Stock Split Proposal ("Adjournment Proposal"). at the 2023-02-03 meeting.

“Proposal 9 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Share Increase Proposal or the Reverse Stock Split Proposal (“Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 14,563,755 9,853,440 800 -”

Allarity Therapeutics, Inc. shareholders approved To approve the issuance of Common Stock in connection with entering into a proposed equity line of credit at prices below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635. at the 2023-02-03 meeting.

“Proposal 8 : To approve the issuance of Common Stock in connection with entering into a proposed equity line of credit at prices below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635. Votes For Votes Against Abstentions Broker Non-Votes 1,809,021 1,287,412 644 203,657”

Allarity Therapeutics, Inc. shareholders voted on To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers. at the 2023-02-03 meeting.

“Proposal 7 : To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executive officers. One Year Two Years Three Years Abstentions Broker Non-Votes 1,271,246 1,844 1,819,787 4,200 203,657”

Allarity Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of our named executive officers at the 2023-02-03 meeting.

“Proposal 6 : To approve, on an advisory basis, the compensation of our named executive officers Votes For Votes Against Abstentions Broker Non-Votes 1,867,802 1,226,875 2,400 203,657”

Allarity Therapeutics, Inc. shareholders rejected To approve the issuance of common stock at a price below the minimum price and in a number that will exceed 20% of our outstanding shares of common stock in accordance with Nasdaq Rule 5635(d) in connection with the shares of common stock that may be issuable upon conversion of shares of Series A Pr at the 2023-02-03 meeting.

“Proposal 5 : To approve the issuance of common stock at a price below the minimum price and in a number that will exceed 20% of our outstanding shares of common stock in accordance with Nasdaq Rule 5635(d) in connection with the shares of common stock that may be issuable upon conversion of shares of Series A Preferred Stock pursuant to an amendment to our Certificate of Designations of Series A Convertible Preferred Stock, as amended, to decrease the conversion price from $9.9061 to $2.00 and the floor price from $1.98 to $0.10, which conversion and floor prices may be further adjusted by the Board subject to the listing requirements of the Nasdaq Stock Market (the “Series A Conversion Nasdaq Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 198,885 1,233,836 - 203,657 1”

Allarity Therapeutics, Inc. shareholders rejected To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the "Board"), effect a reverse stock split with respect to the Company’s issued and outsta at the 2023-02-03 meeting.

“Proposal 4 : To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-2 and 1-for-10 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 15,095,859 9,327,256 - -”

Allarity Therapeutics, Inc. shareholders rejected To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 150,500,000, and to increase the number of our common stock from 30,000,000 to 150,000,000, in substantially the form attached to the Proxy Statement as Appendix A at the 2023-02-03 meeting.

“Proposal 3 : To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 150,500,000, and to increase the number of our common stock from 30,000,000 to 150,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 14,625,515 9,797,600 - -”

Allarity Therapeutics, Inc. shareholders approved To approve the issuance of Common Stock in one or more non-public offerings at a price below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635(d). at the 2023-02-03 meeting.

“Proposal 2 : To approve the issuance of Common Stock in one or more non-public offerings at a price below the minimum price of our Common Stock and in a number that will exceed 20% of our outstanding shares of Common Stock in accordance with Nasdaq Rule 5635(d). Votes For Votes Against Abstentions Broker Non-Votes 1,814,698 1,282,379 - 203,657”

Allarity Therapeutics, Inc. shareholders approved To elect two (2) Class I directors, Soren G. Jensen and Thomas Jensen, to serve until the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified. at the 2023-02-03 meeting.

“Proposal 1 : To elect two (2) Class I directors, Soren G. Jensen and Thomas Jensen, to serve until the 2026 annual meeting of stockholders or until their respective successors are duly elected and qualified. Nominee Votes For Votes Withheld Broker Non-Votes Soren G. Jensen 2,934,725 162,352 203,657 Thomas Jensen 3,067,389 29,688 203,657”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b), 5605(c)(2), 5605(b)(1)(A), 5605(c)(4), 5606(b)).

“February 5, 2023, the Company provided notice to Nasdaq that as a result of Mr. Jensen’s resignation, there are only two independent directors of the Company’s board and audit committee. Under Nasdaq Listing Rule 5605(b), a majority of the board directors must be comprised of independent directors. Under Nasdaq Listing Rule 5605(c)(2), the Company must have an audit committee of three members meeting the criteria of such rule. With Mr. Jensen’s resignation, the Company’s current board consists of four members, two of whom are independent and the Company’s audit committee consist of two members”

Allarity Therapeutics, Inc. amended Letter Agreement with 3i, LP valued at Amendment to extend conversion price modification until terminated by Company and 3i (effective 2023-01-23).

“On January 23, 2023, the Company and 3i amended the Letter Agreement to provide the term Conversion Price will be in effect until terminated by the Company and 3i.”

Soren G. Jensen resigned as Director at Allarity Therapeutics, Inc..

“On January 19, 2023, Mr. Soren G. Jensen gave notice that he will resign as a director, to be effective as of February 4, 2023.”

Gail Maderis resigned as Director at Allarity Therapeutics, Inc..

“On January 19, 2023, Mr. Duncan Moore and Ms. Gail Maderis resigned as directors of Allarity Therapeutics, Inc.”

Duncan Moore resigned as Director at Allarity Therapeutics, Inc..

“On January 19, 2023, Mr. Duncan Moore and Ms. Gail Maderis resigned as directors of Allarity Therapeutics, Inc.”

Allarity Therapeutics, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5450(b)(1)(A)).

“December 21, 2022, the Company received notification from the Nasdaq staff that they have granted the Company an extension of time until April 10, 2023, to regain and evidence compliance with the Rule. No assurance can be given that the Company will be able to regain compliance with the Rule by April 10, 2023, as well as meet other notifications of deficiency subject to previous disclosure on Form 8-K (See Form 8-Ks filed with the SEC on November 25, and December 20, 2022). 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this rep”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(1)(C), 5810(c)(3)(D)).

“December 20, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $5,000,000 under the Nasdaq Listing Rules (the “Listing Rules”). Based on the Company’s MVPHS for the last thirty-one (31) consecutive business days from November 4, 2022 to December 19, 2022, the Company no longer meets the minimum MVPHS requirement set forth in Listing Rule 5450(b)(1)(C). The Notice is only a notificatio”

Allarity Therapeutics, Inc. amended a equity purchase with 3i, LP (effective 2022-12-09).

“On December 9, 2022, the Company and 3i, LP (“3i”), the holder of outstanding shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) entered into a letter agreement which provided that pursuant to Section 8(g) of the Certificate of Designations for the Series A Preferred Stock, the parties agreed that the Conversion Price (as defined in such Certificate of Designations”) was modified to mean the lower of: (i) the Closing Sale Price (as defined in the Certificate of Designations) on the trading date immediately preceding the Conversion Date (as defined in the Certificate of Designations and (ii) the average Closing Sale Price of the common stock for the five trading days immediately preceding the Conversion Date, for the Trading Days (as defined in the Certificate of Designations) through and inclusive of January 19, 2023.”

Allarity Therapeutics, Inc.: Established Series B Preferred Stock with specific voting rights regarding Reverse Stock Split, Share Increase Proposal, and Adjournment Proposal (effective 2022-11-22).

“On November 22, 2022, the Board established the Series B Preferred Stock, par value $0.0001 per share (“Series B Preferred Stock”).”

Allarity Therapeutics, Inc.: Amended Section 12 of Certificate of Designation of Series A Convertible Preferred Stock to grant voting rights, with expiration on February 28, 2023 (effective 2022-11-22).

“On November 22, 2022, the Company amended Section 12 of the Certificate of Designation of Series A Convertible Preferred Stock to provide for voting rights. Subject to a 9.99% beneficial ownership limitation, the holders of Series A preferred stock shall have the right to vote on all matters presented to the stockholders for approval together with the shares of common stock, voting together as a single class, on an “as converted” basis using the “Conversion Price” (initially $9.906 per share before any adjustment) (rounded down to the nearest whole number and using the record date for determining the stockholders of the Company eligible to vote on such matters), except as required by law (including without limitation, the DGCL) or as otherwise expressly provided in the Company’s Certificate of Incorporation or the Certificate of Designations of Series A Convertible Preferred Stock. The voting rights described above shall expire on February 28, 2023, and thereafter holders of preferred”

Allarity Therapeutics, Inc. entered into Purchase Agreement with 3i LP (effective 2022-11-22).

“ovember 22, 2022, the Company entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP. Under the Purchase Agreement, the Company has authorized the sale and issuance of three secured promissory notes, the first note in an aggregate”

Allarity Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“November 21, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of 1.00 per share under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the last 30 consecutive business days from October 10, 2022 to November 18, 2022, the Company no longer meets the minimum bid price requirement set forth in Listing Rule 5550(a)(2). The Notice is only a notific”

Allarity Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $5.0 million.

“Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.”

Jerry McLaughlin was appointed as director at Allarity Therapeutics, Inc..

“To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,”

James G. Cullem was appointed as Director at Allarity Therapeutics, Inc..

“Class III Director : James G. Cullem, whose term will expire at the Company’s third annual meeting of stockholders to be held after December 2021”

David Roth was appointed as Director at Allarity Therapeutics, Inc..

“Class II Director : Dr. David Roth, whose term will expire at the Company’s second annual meeting of stockholders to be held after December 2021”

Thomas Jensen was appointed as Director at Allarity Therapeutics, Inc..

“Class I Director : Thomas Jensen, whose term will expire at the Company’s first annual meeting of stockholders held after December 2021”

Joan Brown was appointed as interim Chief Financial Officer at Allarity Therapeutics, Inc..

“the Board appointed Joan Brown, the Company’s current Director of Financial Reporting, as the interim Chief Financial Officer of the Company effective as of June 29, 2022.”

James Cullem was appointed as interim Chief Executive Officer at Allarity Therapeutics, Inc..

“the Board of Directors of the Company (the “Board”) appointed James Cullem, the Company’s current Chief Business Officer, as the interim Chief Executive Officer of the Company effective as of June 29, 2022.”

Jens Knudsen resigned as Chief Financial Officer at Allarity Therapeutics, Inc..

“Effective as of June 27, 2022, Jens Knudsen resigned from all positions in the Company, and all positions of its subsidiaries, including his role of Chief Financial Officer of the Company.”

Steve Carchedi resigned as Chief Executive Officer at Allarity Therapeutics, Inc..

“Effective as of June 29, 2022, Steve Carchedi resigned from all positions in Allarity Therapeutics, Inc. (the “Company”), and all positions of its subsidiaries, including his role of Chief Executive Officer and as a director of the Company.”